Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI filing briefs · archive

8-K filings in January 2024, explained

73 material Form 8-K filings that 66 companies we cover made with the SEC in January 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

1 of 73 briefs matches

newest first · times in ET
TGTXTG THERAPEUTICS, INC. Jan 10, 7:37 AM ET

TG Therapeutics Reports Preliminary 2023 BRIUMVI Revenue of $89 Million

Neutral earnings Written later 1.017.01

TG Therapeutics preliminarily reported unaudited U.S. BRIUMVI net product revenue of approximately $40 million for the fourth quarter of 2023 and $89 million for the full year, with a year-end 2023 cash position of approximately $215 million. It also set 2024 targets of $220 million to $260 million in full-year BRIUMVI revenue and about $250 million in operating expense, and disclosed a January 7, 2024 license for azer-cel from Precision BioSciences. The filing does not give prior-period comparisons, so the figures alone do not show whether results improved.

  • Preliminary U.S. BRIUMVI net product revenue of approximately $40 million for Q4 2023 and $89 million for full year 2023, unaudited
  • 2024 targets: $41 million to $46 million for Q1 BRIUMVI revenue and $220 million to $260 million for full year; full-year operating expense of approximately $250 million
  • Azer-cel license with Precision BioSciences dated January 7, 2024: $7.5 million upfront and up to $288 million in additional milestone payments, plus royalties
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.